



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

DAVID L. PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 17, 2006

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 17, 2006

Date

David L. Parker

MS AMENDMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RE: *U.S. Patent Application No. 08/844,731 entitled "METHODS OF TREATING AUTOIMMUNE DISEASES USING TYPE ONE INTERFERONS" – Staley A. Brod*
Our reference: CLFR:114US

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references C1-C4.

The Commissioner is authorized to deduct the fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/CLFR:114US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker
Reg. No. 32,165

DLP/mpb

05/01/2006 WADELRI 00000066 501212 08844731
03 FC:1806 180.00 DA

Form PTO-1449 (modified)

APR 28 2006

Atty. Docket No.

Serial No.

CLFR:114US

08/844,731

List of Patents and Publications for Applicant's

Applicant

Staley A. Brod

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

April 21, 1997

Group:

1761

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Brod, "Ingested IFN-alpha: Results of a pilot study in relapsing-remitting MS," <i>Neurology</i> , 57:845-852, 2001.
	C2	Cummins <i>et al.</i> , "Oral use of human alpha interferon in cats," <i>J. Biol. Response Mod.</i> 7:513-423. 1988. (abstract)
	C3	Koren and Fleischmann, "Orally administered interferons suppress bone marrow function," <i>P.S.E.B.M.</i> , 204:155-164, 1993.
	C4	Soos <i>et al.</i> , "Cutting Edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate," <i>J. Immunol.</i> , 169: 2231-2235, 2002.

25646123.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.